Failure of cartilage regeneration: emerging hypotheses and related therapeutic strategies

S Muthu, JV Korpershoek, EJ Novais… - Nature Reviews …, 2023 - nature.com
Osteoarthritis (OA) is a disabling condition that affects billions of people worldwide and
places a considerable burden on patients and on society owing to its prevalence and …

Osteoarthritis, part of life or a curable disease? A bird's‐eye view

M Englund - Journal of Internal Medicine, 2023 - Wiley Online Library
Osteoarthritis (OA) is a chronic joint disease caused by disruption of joint homeostasis by a
variety of systemic and biomechanical factors. The disease is characterized by degradation …

Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)

WM Oo, DJ Hunter - Therapeutic Advances in …, 2022 - journals.sagepub.com
In spite of a major public health burden with increasing prevalence, current osteoarthritis
(OA) management is largely palliative with an unmet need for effective treatment. Both …

Overview of first-line and second-line pharmacotherapies for osteoarthritis with special focus on intra-articular treatment

A Nowaczyk, D Szwedowski, I Dallo… - International Journal of …, 2022 - mdpi.com
Osteoarthritis (OA) can be defined as the result of pathological processes of various
etiologies leading to damage to the articular structures. Although the mechanism of …

The superficial zone of articular cartilage

T Saito - Inflammation and Regeneration, 2022 - Springer
The superficial zone of articular cartilage contributes to smooth joint motion through the
production of proteoglycan 4 (PRG4), also known as lubricin. Recent studies indicate novel …

FDA/Arthritis Foundation osteoarthritis drug development workshop recap: assessment of long-term benefit

JS Kim, S Borges, DJ Clauw, PG Conaghan… - Seminars in arthritis and …, 2022 - Elsevier
Objective To summarize proceedings of a workshop convened to discuss the current state of
science in the disease of osteoarthritis (OA), identify the knowledge gaps, and examine the …

Latest insights in disease-modifying osteoarthritis drugs development

S Li, P Cao, T Chen, C Ding - Therapeutic Advances in …, 2023 - journals.sagepub.com
Osteoarthritis (OA) is a prevalent and severely debilitating disease with an unmet medical
need. In order to alleviate OA symptoms or prevent structural progression of OA, new drugs …

[HTML][HTML] The current role of disease-modifying osteoarthritis drugs

EC Rodriguez-Merchan - Archives of Bone and Joint Surgery, 2023 - ncbi.nlm.nih.gov
Contemporary treatments for osteoarthritis (OA) pursue only to alleviate the pain caused by
the illness. Discovering disease-modifying osteoarthritis drugs (DMOADs) that can induce …

Prospects of disease-modifying osteoarthritis drugs

WM Oo - Rheumatic Disease Clinics, 2024 - rheumatic.theclinics.com
Osteoarthritis (OA) is the most prevalent arthritis with an estimated global prevalence in
2020 of 22.9%(95% confidence interval [CI], 19.8%-26.1%) in persons over 40 years of age …

A white paper on collagen hydrolyzates and ultrahydrolyzates: potential supplements to support joint health in osteoarthritis?

A Mobasheri, A Mahmoudian, U Kalvaityte… - Current rheumatology …, 2021 - Springer
Abstract Purpose of Review Osteoarthritis (OA) is the most common forms of arthritis in the
general population, accounting for more pain and functional disability than any other …